Cargando…
Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that infects at least 10 million people worldwide and is associated with the development of T-cell lymphoma (TCL). The treatment of TCL remains challenging and new treatment options are urgently needed. With the goal of developing a novel t...
Autores principales: | Islam, Shariful, Espitia, Claudia M., Persky, Daniel O., Carew, Jennifer S., Nawrocki, Steffan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310324/ https://www.ncbi.nlm.nih.gov/pubmed/34372612 http://dx.doi.org/10.3390/v13071406 |
Ejemplares similares
-
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015) -
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
por: Kelly, Kevin R., et al.
Publicado: (2017) -
Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
por: Carew, Jennifer S., et al.
Publicado: (2017) -
Oncolytic Viruses for Multiple Myeloma Therapy
por: Calton, Christine M., et al.
Publicado: (2018) -
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
por: Carew, J S, et al.
Publicado: (2013)